Longeveron Announces Phase 2b Trial Misses Primary Endpoint, Initiates Strategic Review
Longeveron (NASDAQ:LGVN) announced that its ELPIS II trial for laromestrocel in infants with hypoplastic left heart syndrome did not meet the primary efficacy endpoint. The study showed no statistically significant improvement in right ventricular ejection fraction at 12 months, raising concerns about the treatment's effectiveness. In response to these results and financial constraints—$10.1 million cash as of June 30—the company has initiated a strategic review process, including engaging an investment bank for potential partnerships or licensing opportunities. The focus is now on capital preservation and identifying viable development paths while managing regulatory uncertainties highlighted by the FDA. Despite the trial's failure to meet its primary endpoint, Longeveron reported no new safety signals in ELPIS II, which could support further interest from partners. Additionally, their aging-related frailty program offers another potential indication for evaluation.
Topics: biotech cardiology stem_cell_treatment strategic_review